Neumora Therapeutics NMRA Ratios (2023-2026)

NASDAQ NMRA
$1.32 -0.03 (-2.59%)
As of: Sep 4, 2026 · 2:20 PM EDT
Reported Financials

Neumora Therapeutics Quarterly Ratios

Periods 12 quarters
Latest Jun 2026

Neumora Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Efficiency
Assets AverageAssets Avg. 520.47M473.20M427.34M378.50M334.75M286.86M240.29M200.83M184.44M172.46M139.56M
Invested CapitalInvested Cap. 287.06M202.33M151.72M158.40M123.64M97.43M
Leverage & Solvency
Interest Coverage RatioInterest Cover -123.94-77.24-28.72-28.51-23.18
Debt Ratio 0.090.110.290.340.42
Times Interest Earned -123.94-77.24-28.72-28.51-23.18
Valuation
Price to EarningsP/E -12.42-10.22-40.83-26.80-29.42-29.14-2.38-2.25-5.36-32.51-6.76-7.41
Price to BookP/B 1.282.365.174.136.655.970.710.652.303.005.117.17
Enterprise Value 149.24M654.63M1,770.74M1,201.43M1,792.91M1,406.55M-87.61M-98.83M132.58M129.40M214.23M202.59M
EV to EBIT -2.62-5.74-29.48-18.82-23.39-22.351.231.83-2.30-2.21-4.05-4.80
EV to EBITDA -2.62-5.74-29.48-18.82-23.39-22.351.231.83-2.30-2.21-4.05-4.80
Market Capitalization 658.81M1,108.61M2,193.45M1,573.07M2,134.22M1,714.13M161.75M118.75M304.10M311.93M361.30M319.42M
Price to FCFP/FCF -13.78-21.53-51.06-28.01-63.74-34.05-2.72-2.27-6.52-6.50-7.79-8.08
EV to FCF -3.12-12.71-41.22-21.39-53.55-27.941.471.89-2.84-2.70-4.62-5.13
EV to CFO -3.12-12.73-41.22-21.39-53.55-27.941.471.89-2.84-2.70-4.62-5.13
Return Ratios
Return on Capital Employed [ROCE]ROCE -50.89%-60.86%-72.92%-90.71%-86.42%-106.13%-120.72%-140.35%-158.67%-156.72%-188.96%
Return on Invested Capital [ROIC]ROIC -138.81%-122.86%-122.76%-146.34%
Return on Assets [ROA]ROA -45.87%-53.62%-64.10%-77.52%-72.83%-89.96%-104.91%-117.66%-101.43%-100.04%-116.71%